http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1816124-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4740cdb70f93e8b1db8c773b6d5473a3
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5038
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5014
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4406
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-89
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-38
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-89
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4406
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
filingDate 2000-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf12c5cd523825bdbc85993541c8d39d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e48ddacec1ce3f56d96ecf0ffa4458b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_57440dc1cf4b7f2e9143e69ddae4a527
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea67eb6a8767450ecc9c57b46fc31cf7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fee2f0110ea0e9c0f0f947f9885df87e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c78923cd3af81b4c382baa68353037f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_67db6875208ce615a2b66cd004e5a3ee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d06a9f19dcbd2876c95a741f46bb1975
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41220aacb0722f3fea422963db49e10b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c6aaf23b6afbd50199aeb0291d5e7de7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9003804108a589f87e023095cd974077
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93b5fed55748501e43ce7a7f195f9bd4
publicationDate 2009-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-1816124-A3
titleOfInvention Inhibitors of cellular niacinamide mononucleotide formation and their use in cancer therapy
abstract New biologically active compounds are described which inhibit the cellular formation of niacinamide mononucleotide, an essential intermediate of the NAD(P) biosynthesis in the cell. These compounds can represent the active ingredient of a pharmaceutical composition for the treatment of cancers, leukaemias or for immunosuppression. Furthermore, screening methods are described as a tool for detecting the above active compounds, and for examination of a given cell type for its dependency on niacinamide as a precursor for NAD synthesis.
priorityDate 1999-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9748696-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9748397-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID936
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395240

Total number of triples: 63.